In the past week, ITOS stock has gone down by -0.80%, with a monthly gain of 31.44% and a quarterly plunge of -3.64%. The volatility ratio for the week is 7.40%, and the volatility levels for the last 30 days are 8.10% for ITeos Therapeutics Inc The simple moving average for the past 20 days is 17.09% for ITOS’s stock, with a -24.19% simple moving average for the past 200 days.
Is It Worth Investing in ITeos Therapeutics Inc (NASDAQ: ITOS) Right Now?
ITOS has 36-month beta value of 1.39. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ITOS is 33.10M, and currently, short sellers hold a 6.09% ratio of that float. The average trading volume of ITOS on May 01, 2025 was 384.58K shares.
ITOS) stock’s latest price update
The stock of ITeos Therapeutics Inc (NASDAQ: ITOS) has increased by 2.07 when compared to last closing price of 7.25.Despite this, the company has seen a loss of -0.80% in its stock price over the last five trading days. globenewswire.com reported 2025-04-28 that – Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 – Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 – Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the first quarter ended March 31, 2025 and provided a business update.
Analysts’ Opinion of ITOS
Many brokerage firms have already submitted their reports for ITOS stocks, with Wells Fargo repeating the rating for ITOS by listing it as a “Overweight.” The predicted price for ITOS in the upcoming period, according to Wells Fargo is $31 based on the research report published on August 13, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ITOS reach a price target of $37. The rating they have provided for ITOS stocks is “Buy” according to the report published on May 05th, 2021.
Robert W. Baird gave a rating of “Outperform” to ITOS, setting the target price at $45 in the report published on October 08th of the previous year.
ITOS Trading at 10.88% from the 50-Day Moving Average
After a stumble in the market that brought ITOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.53% of loss for the given period.
Volatility was left at 8.10%, however, over the last 30 days, the volatility rate increased by 7.40%, as shares surge +28.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.93% lower at present.
During the last 5 trading sessions, ITOS fell by -0.40%, which changed the moving average for the period of 200-days by -55.21% in comparison to the 20-day moving average, which settled at $6.32. In addition, ITeos Therapeutics Inc saw -3.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITOS starting from Gall Matthew, who purchase 5,000 shares at the price of $7.73 back on Nov 19 ’24. After this action, Gall Matthew now owns 65,429 shares of ITeos Therapeutics Inc, valued at $38,635 using the latest closing price.
Stock Fundamentals for ITOS
Current profitability levels for the company are sitting at:
- -4.35 for the present operating margin
- 0.99 for the gross margin
The net margin for ITeos Therapeutics Inc stands at -3.74. The total capital return value is set at -0.25. Equity return is now at value -23.68, with -20.30 for asset returns.
Based on ITeos Therapeutics Inc (ITOS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -19.7.
Currently, EBITDA for the company is -159.53 million with net debt to EBITDA at 1.07. When we switch over and look at the enterprise to sales, we see a ratio of 3.76. The receivables turnover for the company is 10.7for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.13.
Conclusion
To put it simply, ITeos Therapeutics Inc (ITOS) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
